Edgewise Therapeutics, Inc. (EWTX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Orbimed Advisors LLC entity

Director

$26.74M (7)

—

+$26.74M

443,792

0.4086%

$19.26M

—

Peter A. Thompson

Director

$26.74M (7)

—

+$26.74M

443,792

0.4086%

$19.26M

—

Alan J Russell

Chief Scientific Officer

—

$23.50M (54) scheduled

−$23.50M

31,466

0.0290%

$1.37M

−88.5%

Novo Holdings A/S entity

10% owner

$15.00M (2)

—

+$15.00M

6,071,703

5.59%

$263.55M

—

James E Flynn

10% owner

$10.00M (1)

—

+$10.00M

3,933,137

3.62%

$170.72M

—

Joanne M. Donovan

CMO

—

$5.74M (17) scheduled

−$5.74M

8,625

0.0079%

$374.38K

−27.9%

R Michael Carruthers

Chief Financial Officer

—

$5.09M (9) scheduled

−$5.09M

86,162

0.0793%

$3.74M

+682.2%

John R Moore

General Counsel

—

$4.45M (35) scheduled

−$4.45M

17,697

0.0163%

$768.16K

+241.2%

Badreddin Edris

Director

—

$3.40M (5) scheduled

−$3.40M

19,820

0.0182%

$860.32K

0.0%

Behrad Derakhshan

Chief Business Officer

—

$2.05M (13) scheduled

−$2.05M

31,826

0.0293%

$1.38M

+221.9%

Kevin Koch

President and CEO

—

$1.34M (10) scheduled

−$1.34M

52,488

0.0483%

$2.28M

—

Marc Semigran

Chief Development Officer

—

$881.92K (2) scheduled

−$881.92K

6,716

0.0062%

$291.52K

0.0%

Jonathan C Fox

Director

$300.36K (2)

—

+$300.36K

25,141

0.0231%

$1.09M

—

Jonathan D Root

Director

$250.00K (1)

—

+$250.00K

15,625

0.0144%

$678.23K

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

681,812

0.6278%

$29.60M

—

Edgewise Therapeutics, Inc.

What the insiders did Net buying

By person